Enteric Dysmotility in Mitochondrial Neurogastrointestinal Encephalomyopathy Patients Detected by High-resolution

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Mitochondrial neurogastrointestinal encephalopathy (MNGIE) is an ultra-rare mitochondrial disease caused by mutations of the gen that codifies the enzyme thymidine phosphorylase The genetic defect results in systemic accumulation of the nucleosides thymidine and deoxyuridine. Clinically MNGIE is characterized by a combination of gastrointestinal and neurological manifestations, including severe gastrointestinal dysmotility, cachexia, ptosis, external ophthalmoplegia and sensorimotor neuropathy. Gastrointestinal symptoms are the most frequent first manifestation of the disease, and include early satiety, nausea, dysphagia, postprandial emesis, abdominal pain, abdominal distention, and diarrhea. The disease is relentlessly progressive and the cause of death is primarily related to digestive dysmotility. However, the specific motor dysfunctions that produce the symptoms, i.e., the underlying mechanisms, remain uncertain.

Eligibility
Participation Requirements
Sex: All
View:

• diagnosis of MNGIE disease established by thymidine phosphorylase activity and mitochondrial mutation analysis.

Locations
Other Locations
Spain
Hospital Universitari Vall d'Hebron
RECRUITING
Barcelona
Contact Information
Primary
Carolina Malagelada, MD
cmalagelada@vhebron.net
+34932746259
Backup
Luis Alcala, MD
lgalcala1986@gmail.com
34 695101188
Time Frame
Start Date: 2018-02-01
Estimated Completion Date: 2025-12
Participants
Target number of participants: 6
Related Therapeutic Areas
Sponsors
Leads: Hospital Universitari Vall d'Hebron Research Institute

This content was sourced from clinicaltrials.gov